MENU
+Compare
ALPMY
Stock ticker: OTC
AS OF
Aug 27 closing price
Price
$10.96
Change
-$0.07 (-0.63%)
Capitalization
19.56B

ALPMY Astellas Pharma, Inc. Forecast, Technical & Fundamental Analysis

Astellas Pharma Inc is a specialty global pharmaceutical company... Show more

ALPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ALPMY with price predictions
Aug 27, 2025

ALPMY saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for ALPMY moved out of overbought territory on August 20, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 63 similar instances where the indicator exited the overbought zone. In of the 63 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ALPMY moved out of overbought territory on August 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on August 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ALPMY as a result. In of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ALPMY turned negative on August 25, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALPMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ALPMY broke above its upper Bollinger Band on August 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALPMY advanced for three days, in of 293 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 195 cases where ALPMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.958) is normal, around the industry mean (9.451). ALPMY's P/E Ratio (57.375) is considerably higher than the industry average of (23.804). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.849). ALPMY has a moderately high Dividend Yield (0.046) as compared to the industry average of (0.027). P/S Ratio (1.523) is also within normal values, averaging (3.415).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALPMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALPMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.

View a ticker or compare two or three
ALPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ALPMY is expected to report earnings to fall 25.63% to 18 cents per share on October 29

Astellas Pharma, Inc. ALPMY Stock Earnings Reports
Q3'25
Est.
$0.19
Q2'25
Beat
by $0.12
Q1'25
Beat
by $41.06
Q4'24
Missed
by $0.41
Q3'24
Beat
by $0.01
The last earnings report on July 30 showed earnings per share of 25 cents, beating the estimate of 13 cents. With 91.41K shares outstanding, the current market capitalization sits at 19.56B.
A.I.Advisor
published Dividends

ALPMY paid dividends on June 17, 2024

Astellas Pharma, Inc. ALPMY Stock Dividends
А dividend of $0.22 per share was paid with a record date of June 17, 2024, and an ex-dividend date of March 27, 2024. Read more...
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
2-5-1, Nihonbashi-Honcho
Phone
+81 332443000
Employees
16243
Web
http://www.astellas.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FFLS25.650.10
+0.39%
Future Fund Long/Short ETF
WDI14.980.02
+0.13%
Western Asset Diversified Income Fund
CCNR28.570.03
+0.12%
ALPS/CoreCommodity Natural Resources ETF
ACWI133.680.05
+0.04%
iShares MSCI ACWI ETF
CWS69.46-0.07
-0.10%
AdvisorShares Focused Equity ETF

ALPMY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALPMY has been loosely correlated with ALPMF. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ALPMY jumps, then ALPMF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALPMY
1D Price
Change %
ALPMY100%
-0.67%
ALPMF - ALPMY
38%
Loosely correlated
N/A
OPHLY - ALPMY
33%
Loosely correlated
+0.28%
CHGCY - ALPMY
22%
Poorly correlated
+1.36%
DSNKY - ALPMY
21%
Poorly correlated
-1.02%
OTSKY - ALPMY
20%
Poorly correlated
-0.90%
More